Multiple-matrix metabolomics analysis for the distinct detection of colorectal cancer and adenoma
- PMID: 38642214
- DOI: 10.1007/s11306-024-02114-1
Multiple-matrix metabolomics analysis for the distinct detection of colorectal cancer and adenoma
Abstract
Objectives: Although colorectal cancer (CRC) is the leading cause of cancer-related morbidity and mortality, current diagnostic tests for early-stage CRC and colorectal adenoma (CRA) are suboptimal. Therefore, there is an urgent need to explore less invasive screening procedures for CRC and CRA diagnosis.
Methods: Untargeted gas chromatography-mass spectrometry (GC-MS) metabolic profiling approach was applied to identify candidate metabolites. We performed metabolomics profiling on plasma samples from 412 subjects including 200 CRC patients, 160 CRA patients and 52 normal controls (NC). Among these patients, 45 CRC patients, 152 CRA patients and 50 normal controls had their fecal samples tested simultaneously.
Results: Differential metabolites were screened in the adenoma-carcinoma sequence. Three diagnostic models were further developed to identify cancer group, cancer stage, and cancer microsatellite status using those significant metabolites. The three-metabolite-only classifiers used to distinguish the cancer group always keeps the area under the receiver operating characteristic curve (AUC) greater than 0.7. The AUC performance of the classifiers applied to discriminate CRC stage is generally greater than 0.8, and the classifiers used to distinguish microsatellite status of CRC is greater than 0.9.
Conclusion: This finding highlights potential early-driver metabolites in CRA and early-stage CRC. We also find potential metabolic markers for discriminating the microsatellite state of CRC. Our study and diagnostic model have potential applications for non-invasive CRC and CRA detection.
Keywords: Colorectal adenoma; Colorectal cancer; GC-MS; Metabolomics; Microsatellite status.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Azad, R. K., & Shulaev, V. (2019). Metabolomics technology and bioinformatics for precision medicine. Briefings in Bioinformatics, 20, 1957–1971. https://doi.org/10.1093/bib/bbx170 . - DOI - PubMed
-
- Bauermeister, A., Mannochio-Russo, H., Costa-Lotufo, L. V., Jarmusch, A. K., & Dorrestein, P. C. (2022). Mass spectrometry-based metabolomics in microbiome investigations. Nature Reviews Microbiology, 20, 143–160. https://doi.org/10.1038/s41579-021-00621-9 . - DOI - PubMed
-
- Bryan, S., Masoud, H., Weir, H. K., Woods, R., Lockwood, G., Smith, L., Brierley, J., Gospodarowicz, M., & Badets, N. (2018). Cancer in Canada: Stage at diagnosis. Health Reports, 29, 21–25. - PubMed
-
- Camp, E. R., Patterson, L. D., Kester, M., & Voelkel-Johnson, C. (2017). Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer. Cancer Biology & Therapy, 18, 640–650. https://doi.org/10.1080/15384047.2017.1345396 . - DOI
-
- Chen, F., Dai, X., Zhou, C. C., Li, K. X., Zhang, Y. J., Lou, X. Y., Zhu, Y. M., Sun, Y. L., Peng, B. X., & Cui, W. (2022). Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut, 71, 1315–1325. https://doi.org/10.1136/gutjnl-2020-323476 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
- Y21049/a Project Funded by the Jiangsu Provincial Hospital of Traditional Chinese Medicine
- No.22KJB310003/Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Natural Science Foundation of Higher Education
- No.2022YFC3500200, 2022YFC3500202/key project of the Grants from the National Key R&D Program of China
- No.81930117/National Natural Science Foundation of China
- ZYYCXTD-C-202208/Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
LinkOut - more resources
Miscellaneous